Based in Redwood City, California, Graybug Vision, Inc. is a biopharmaceutical company focused on developing medications for retinal and optic nerve diseases. The company's lead product candidate, GB-102, is a microparticle depot formulation of sunitinib in clinical testing for treating age-related macular degeneration and diabetic macular edema. Graybug Vision, Inc. has also developed GB-401, an implant injection of a beta-adrenergic receptor inhibitor for the treatment of primary open-angle glaucoma.